Nutriband Sells 90% Pocono Stake for $5M, Secures FDA Type C Meeting Approval
Nutriband sold 90% of its Pocono subsidiary to EarthVision Bio for $5 million with no shareholder dilution, retaining a 10% stake. It declared a 25% preferred stock dividend, secured FDA Type C meeting approval for AVERSA fentanyl, completed manufacturing scale-up, and was added to four Russell indexes.
1. Strategic Moves Boost Shareholder Value
In 2025, Nutriband executed a landmark transaction by selling 90% of its Pocono subsidiary to EarthVision Bio for $5 million in cash, with no dilution to existing shareholders. The company retains a 10% stake in the new entity and potential upside if EarthVision pursues a public listing. Management emphasized its reluctance to pursue dilutive financing and highlighted the expected positive impact of this cash infusion on working capital and R&D funding.
2. 25% Preferred Stock Dividend Strengthens Equity Base
On July 25, 2025, Nutriband declared and subsequently paid on August 5 a 25% preferred stock dividend to all common shareholders of record, issuing one preferred share for every four common shares held. Each preferred share is convertible into one common share upon FDA approval of the AVERSA Fentanyl patch and, if unconverted, will receive an annual cash dividend from company profits as determined by the board, effectively creating a non-dilutive mechanism to reward long-term holders.
3. AVERSA™ Fentanyl Advances Toward Commercialization
Nutriband’s lead product, AVERSA™ Fentanyl, secured multiple regulatory and manufacturing milestones in 2025: in February, the U.S. Patent Office issued a Notice of Allowance for its transdermal abuse-deterrent patent; the company expanded its exclusive development partnership with Kindeva Drug Delivery under a revised cost-sharing agreement; in June, USPTO granted patent No. 12,318,492 titled “Abuse and Misuse Deterrent Transdermal Systems,” and commercial manufacturing scale-up was completed; and in August, a Type C meeting with the FDA validated the Chemistry, Manufacturing and Controls pathway from IND submission through a 505(b)(2) NDA.
4. Index Inclusions and 2026 Catalysts
In July 2025, Nutriband was added to four Russell indexes—Microcap, Microcap Growth, 3000E and 3000E Growth—broadening institutional awareness and potential passive inflows. Looking ahead, management pointed to the October 2026 expiration of warrants issued in the 2021 IPO as a key event likely to reduce overhang and volatility, and highlighted the January 24, 2026 annual shareholder meeting as an opportunity for further updates on the AVERSA commercialization timeline.